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Merkel cell carcinoma (MCC) is an aggressive
tumor of the skin and mucous membranes that
typically occurs in elderly white men and in immu-
nosuppressed individuals. The reported incidence of
MCC has tripled over the last 20 years in the United
States1 from 0.15 to 0.44 cases per 100 000 between
1986 and 2001.2 In light of the poor prognosis and
high risk for recurrence, metastasis, and death
associated with MCC, this increasing trend is of
concern. The risk factors for MCC are similar to
those for other skin cancers, mainly ultraviolet light
exposure, older age, T-cell immunosuppression, fair
skin, and male sex.3,4 Although a rare tumor, MCC is
seen more frequently in the immunosuppressed
population, and immunosuppressed MCC patients
tend to be younger at diagnosis and have less
favorable disease outcomes. Specifically, HIV
positivity,1 lymphocytic leukemia,2 and iatrogenic
immunosuppression after organ transplantation3
confer an increased risk of MCC.
Here we report 2 cases of MCC occurring in
organ transplant recipients (OTRs), illustrating how
iatrogenic immunosuppression in the setting of
organ transplantation can impact tumor progression
and potentially decrease survival. We summarize
current evidence regarding the pathogenesis, stag-
ing, and treatment of MCC and bring forth our
recommendation to monitor high-risk OTR with
frequent skin examinations. MCC has a poor
prognosis and its management remains a challenge.
Early recognition can improve clinical outcomes
and disease-specific and overall survival in the
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Patient 1
A 64-year-old male kidney transplant recipient
with Fitzpatrick skin type II received a kidney
transplant in 2007 because of diabetic nephropathy
and was maintained on tacrolimus and mycopheno-
late mofetil. He was treated with Mohs surgery for a
basal cell carcinoma and a squamous cell carcinoma
in situ of the face in 2012. He presented again in 2013
for the evaluation of a lesion on the dorsal surface of
his left forearm (Fig 1, A).
On examination, a 2- 3 1.5-cm erythematous
nodule was noted. Histologic analysis of a biopsy
specimen found sheets of small round blue cells with
numerous mitotic figures infiltrating the dermis and
extending into the subcutaneous tissue (Fig 1, B).
Immunohistochemistry analysis found characteristic
MCC features, including paranuclear dotlike staining
for CK20.
Fluorodeoxyglucose-positron emission tomogra-
phy scan did not find any abnormal focal uptake in
the left upper extremity or any evidence of axillary
adenopathy. Sentinel lymph node biopsy of the left
axilla did not find any evidence of metastasis.
Management consisted of wide local excision with
2.5-cm margins and 25 sessions of local (55 Gy) and
axillary (45 Gy) external beam radiation over
5 weeks. Three months after completing radiation,JAAD Case Reports 2015;1:S29-32.
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Fig 1. A, Rapidly growing 2- 3 1.5-cm erythematous nodule on dorsal left arm of patient 1.
B, Sheets of small round uniformed blue cells infiltrating the dermis in patient 1. C, Rapidly
growing 2- x 3-cm exophytic erythematous nodule on the left side of the neck inpatient 2.
D, Immunostaining for neurofilament demonstrating pathognomonic paranuclear dotlike
expression in patient 2.
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1- 3 1-cm erythematous nodule on the ventral
surface of left forearm, outside of the radiation field.
Biopsy results of the lesion showed pathology
consistent with MCC. He is currently scheduled to
have complementary radiologic imaging for
adequate staging and therapeutic guidance.Patient 2
A 68-year-old Hispanic man with Fitzpatrick
skin type IV received a lung transplant in 2001
for silicosis and was maintained on an immuno-
suppressive regime of prednisone and mycophe-
nolate mofetil before being switched to sirolimus
in 2013. He was followed closely by the derma-
tology department for multiple posttransplant cuta-
neous SCCs, despite chemoprophylaxis with
acitretin, photodynamic therapy, and topical 5-
fluorouracil.
Twelve years after the transplant, the patient
presented with a rapidly growing 2- 3 3-cm
exophytic erythematous nodule with an underlying
firm mass on the left side of the neck (Fig 1, C ). A
biopsy found sheets of basaloid cells with finelystippled chromatin, nuclear molding, and numerous
mitotic figures. Immunostaining for neurofilament
showed paranuclear dotlike positivity, consistent
with MCC, and D2-40 immunostaining confirmed
lymphovascular invasion (Fig 1, D).
Positron emission tomography/computed tomog-
raphy found intraparotid and level II-VA and VB
cervical lymphadenopathy, consistent with nodal
metastasis. His case was presented at the multi-
disciplinary tumor board, and he was deemed to
be a poor surgical candidate, given the rapidity of
growth and poor chance for surgical control. The
patient received 66 Gy external beam radiation over
6 weeks and is currently in follow-up with guarded
prognosis. He has had no evidence of MCC disease
for 4 months.DISCUSSION
These cases illustrate the aggressive nature of
MCC in the setting of organ transplantation. The
patients had the additional risk factors of male
sex and age over 60.4 In a study examining 8 solid
OTRs with MCC and 89 immunocompetent control
subjects, Arron et al5 reported that OTR with MCC
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(95% confidence interval [CI], 1.57-10.95), a 10-fold
increased hazard for overall mortality (95% CI,
3.06-35.98), and a 12-fold increased hazard
for MCC-specific mortality (95% CI, 2.67-53.08),
adjusted for sex, age, and stage at presentation.
OTRs also had a significantly lower 1-year overall
survival rate (47% vs 89%) and a significantly lower
1-year MCC-specific survival rate (56% vs 95%).5
Although the approach to MCC in OTR follows
general management guidelines, dermatologists
should act quickly to coordinate multidisciplinary
care.
The evaluation of OTRs with MCC includes a
complete physical examination and a low threshold
for radiologic imaging to screen for nodal and
metastatic spread. Histopathology and immunohis-
tochemistry of the primary lesion can be used to
confirm the diagnosis of MCC, and sentinel lymph
node biopsy can identify microscopic nodal invasion
in patients with negative node status on clinical
examination and radiologic imaging.6 Although the
efficacy and cost effectiveness of sentinel lymph
node biopsy needs further evaluation, patients with
negative node status determined by pathology have
a better outcome (75% at 5 years) than those who
only undergo clinical nodal evaluation (59%;
P \ .0001).7 The presence of nodal disease can
provide information about prognosis and help
identify the draining nodal basin for additional
treatment via completion lymph node dissection or
adjuvant radiation therapy.
The American Joint Committee on Cancer
published a new international consensus MCC
staging system, which can be used to determine
prognosis and guide treatment decisions in our
patients.7 The decision to defer surgery in patient 2
was primarily influenced by the rapid growth rate,
size larger than 2 cm, and presence of vascular and
lymphatic invasion, which are high-risk features of
MCC associated with higher rates of regional and
distant metastasis and postsurgical local recurrence.
The reported 5-year survival rates for local, nodal,
and metastatic disease are 64%, 39%, and 18%,
respectively.7 In this unfortunate setting, surgical
control was deemed unlikely. In contrast, patient 1
was considered a good candidate for wide local
excision and postoperative adjuvant radiation
therapy for his primary tumor. Despite these
measures, a local recurrence developed outside of
the radiation field.
The optimal treatment of patients with MCC is a
subject of debate. Ongoing investigational studies
are using molecular-targeted therapies and immu-
notherapy in select patient populations. Surgicalexcisionwith negativemargins remains the preferred
treatment for local disease, and radiation therapy
is recommended for both regional and local
tumors with high-risk features. Despite aggressive
management with wide local excision and radiation
therapy, local recurrence, distant metastasis, and
in-transit metastasis are common. Most recurrences
occur within 2 years of the primary tumor, with
local recurrence, nodal metastasis, and distant
metastasis usually noted at 4 months, 8 months,
and 18 months after excision of the primary lesion,
respectively.8 Patient 1 had a second lesion 3 months
after completing radiotherapy. Considering the
anatomic location of his second tumor compared
with the first, it is likely that the second tumor is a
local recurrence or an in-transit metastasis. There is
no evidence supporting the use of adjuvant
chemotherapy in regional MCC disease,9 which can
actually worsen the prognosis because of the
associated increase of immunosuppression and
systemic side effects.10,11 Palliative chemotherapy
has a high response rate but a limited duration of
response in metastatic disease.12,13 In OTR with very
aggressive MCC, a reduction or revision of immuno-
suppression can be considered, carefully balancing
the benefits of this intervention against the risk of
graft failure. However, the chances of reversing
advanced disease are slim, and quality of life is an
important consideration.
MCC is a late complication of transplantation.
Arron et al5 found that the time from transplantation
to diagnosis ranged from 1.6 to 24.8 years (median,
5.0; interquartile range, 4.6-7.4). The risk of MCC
recurrence can be minimized by aggressive and
careful management, where a multidisciplinary
approach based on prevention, collaboration, and
early intervention can improve outcomes in high-risk
patients. Most MCCs recur within 3 years of diag-
nosis,10 so a full skin and regional lymph node
examination is recommended, at least every
3 months in the first year, every 6 months in the
second year, and annually thereafter. Dermatologists
are an essential resource to the transplant team in the
care of transplanted patients with advanced-stage
tumors. Dermatologists should have an increased
level of vigilance in their evaluation of OTR,
especially in the presence of additional risk factors
for MCC.
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